![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, January 13, 2021 5:11:39 PM
So far, strongest argument I've seen is on page 9 within section C.
As analogously illustrated by the California Stem Cell case, porting the minimal manipulation requirement from section 1271.10(a) into section 1271.15(b) would effectively mean that the SSP Exception could not apply to any cell implantation procedures, because isolating cells from tissue would always, by FDA’s interpretation, constitute more than minimal manipulation of the tissue. Since the SSP Exception by its very terms envisions its application to cell implantation procedures, FDA’s interpretation simply cannot be correct.
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM